RPL18 and neoplasm: This increase in therapeutic efficacy could not be attributed to an increased presence of tumor-specific (Rpl18 Tm+) or reovirus-specific (μ1133–140 Tm+) CD8+ T cells in the circulation, because their frequencies were similar between the group that received Reo&CD3-bsAb therapy and the group that received additional αTGF-β therapy (Fig. 6F).